Budesonide treatment of professional athletes and anti-doping testing- case studies - Publication - Bridge of Knowledge

Search

Budesonide treatment of professional athletes and anti-doping testing- case studies

Abstract

According to the World Anti-Doping Agency (WADA) Prohibited List, glucocorticosteroids are prohibited in competition and only when administered by oral, intravenous, intramuscular or rectal routes. Up to now, in order to differentiate whether glucocorticosteroids were administered by one of the prohibited routes or not, a specific reporting limit for urinary concentrations of parent compounds and their metabolites was established at 30 ng/mL. Additionally, the new specific regulation starting from 1 September 2014 for budesonide have been introduced that the β-hydroxybudesonide shall be targeted. Budesonide is a glucocorticosteroid used mainly by inhalation for asthma management. Interestingly, anti-doping laboratory statistics show that budesonide adverse analytical findings (AAF) constitute almost 50% of all reported glucocorticosteroid AAFs, even though budesonide possesses a very low systemic activity which may cause performance enhance effects. This work presents the results of five studies of controlled budesonide administration carried out on professional athletes. The samples were analyzed by using a quantitative HPLC/MS/MS method for 16α-hydroxyprednisolone, the most abundant budesonide metabolite in urine. Our data clearly show that inhalation of budesonide at least 12 h before a competition at therapeutic doses leads to appearance of the main budesonide metabolite in concentrations exceeding prior reporting limit for this compound.

Authors (9)

  • Photo of  Paweł Kaliszewski

    Paweł Kaliszewski

    • Institute of Sport, Warszawa Department of Anti-Doping Research
  • Photo of  Danuta Kończak

    Danuta Kończak

    • Institute of Sport, Warszawa Department of Anti-Doping Research
  • Photo of  Piotr Chołbiński

    Piotr Chołbiński

    • Institute of Sport, Warszawa Department of Anti-Doping Research
  • Photo of  Mariola Wicka

    Mariola Wicka

    • Institute of Sport, Warszawa Department of Anti-Doping Research
  • Photo of  Dorota Michalak

    Dorota Michalak

    • Institute of Sport, Warszawa Department of Anti-Doping Research
  • Photo of dr inż. Dorota Kwiatkowska

    Dorota Kwiatkowska dr inż.

    • Institute of Sport, Warszawa Department of Anti-Doping Research
  • Photo of  Sylwia Lewandowska-Pachecka

    Sylwia Lewandowska-Pachecka

    • Medical University of Warsaw Faculty of Pharmacy
  • Photo of  Andrzej Pokrywka

    Andrzej Pokrywka

    • University of Zielona Góra Faculty of Medicine and Health Sciences

Cite as

Full text

download paper
downloaded 50 times
Publication version
Accepted or Published Version
License
Creative Commons: CC-BY-NC open in new tab

Keywords

Details

Category:
Articles
Type:
artykuł w czasopiśmie wyróżnionym w JCR
Published in:
Acta Poloniae Pharmaceutica - Drug Research no. 73, pages 229 - 237,
ISSN: 0001-6837
Language:
English
Publication year:
2016
Bibliographic description:
Kaliszewski P., Kończak D., Chołbiński P., Wicka M., Michalak D., Kwiatkowska D., Lewandowska-Pachecka S., Namieśnik J., Pokrywka A.: Budesonide treatment of professional athletes and anti-doping testing- case studies// Acta Poloniae Pharmaceutica - Drug Research. -Vol. 73, nr. 1 (2016), s.229-237
Verified by:
Gdańsk University of Technology

seen 480 times

Recommended for you

Meta Tags